Collaboration aids quantitative biomarker prediction

Clarient and Definiens have established a strategic partnership to employ a series of image analysis platforms for Clarient's in-house research and development, and web-based customer portal Pathsite. Under a five-year collaborative agreement, Clarient and Definiens plan to develop and commercialise tools that will help to evaluate quantitative biomarkers that predict cancer treatment response to targeted therapies.

Ken Bloom, MD, Clarient's chief medical officer, said: 'The availability of image analysis tool sets is essential as we enter the age of personalised medicine. Many of the assays in development assess several intracellular processes simultaneously, and it is critical that we develop algorithms that localise and quantify key markers. We now have the ability to provide a number of image analysis tools across a wide range of technologies to help facilitate biomarker assessment for our biopharma clients in the clinical marketplace. The Definiens agreement provides us with access to a team of scientists that have extensive experience in software development and biomarker analysis for applications in the life sciences.'

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon

For functionality and security for externalised research, software providers have turned to the cloud, writes Sophia Ktori


Robert Roe looks at the latest simulation techniques used in the design of industrial and commercial vehicles


Robert Roe investigates the growth in cloud technology which is being driven by scientific, engineering and HPC workflows through application specific hardware


Robert Roe learns that the NASA advanced supercomputing division (NAS) is optimising energy efficiency and water usage to maximise the facility’s potential to deliver computing services to its user community


Robert Roe investigates the use of technologies in HPC that could help shape the design of future supercomputers